Oruka Therapeutics, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities
Oruka Therapeutics, Inc. (ORKA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities of $54.00 thousand as of 2024-08-29, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities · last filed 2026-03-12
- 2024-08-29: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities $54.00K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities |
|---|---|
| 2024-08-29 | $54.00K 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |